https://scholars.lib.ntu.edu.tw/handle/123456789/517982
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Chan H.-Y. | en_US |
dc.contributor.author | Lin W.-W. | en_US |
dc.contributor.author | Lin S.-K. | en_US |
dc.contributor.author | TZUNG-JENG HWANG | en_US |
dc.contributor.author | Su T.-P.T. | en_US |
dc.contributor.author | Chiang S.-C. | en_US |
dc.contributor.author | HAI-GWO HWU | en_US |
dc.creator | Chan H.-Y.;Lin W.-W.;Lin S.-K.;Tzung-Jeng Hwang;Su T.-P.T.;Chiang S.-C.;Hwu H.-G. | - |
dc.date.accessioned | 2020-10-23T11:55:05Z | - |
dc.date.available | 2020-10-23T11:55:05Z | - |
dc.date.issued | 2007 | - |
dc.identifier.issn | 0160-6689 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-33846860210&doi=10.4088%2fJCP.v68n0104&partnerID=40&md5=3d41303e7fd6f82e713717709b2bc7e8 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/517982 | - |
dc.description.abstract | Objective: Asian populations may differ from other races in response to antipsychotics. Studies of aripiprazole in Asian populations are scarce. This study aimed to investigate the efficacy, safety, and tolerability of aripiprazole in Chinese patients with acute schizophrenia or schizoaffective disorder. Method: This 4-week, double-blind, randomized, parallel study was conducted in 5 medical centers in Taiwan between March 2004 and January 2005. A total of 83 patients with a primary DSM-IV diagnosis of schizophrenia or schizoaffective disorder were randomly assigned (with a randomization ratio of 3:2) to 15 mg/day of aripiprazole (N = 49) or 6 mg/day of risperidone (N = 34). Efficacy measures included the Positive and Negative Syndrome Scale (PANSS) total, positive, and negative scores and Clinical Global Impressions-Severity of Illness (CGI-S) and -Improvement scale scores. Extrapyramidal symptoms (EPS), weight gain, serum prolactin level, QTc interval, and self-reported adverse events were assessed as measures of safety and tolerability. Results: Both the aripiprazole and risperidone groups showed statistical improvement from baseline in PANSS total, PANSS positive, PANSS negative, and CGI-S scores at study endpoint (all p < .001). Significant improvement was noted in the first week of treatment for both treatment groups. There were no significant differences in efficacy measures between treatment groups. Aripiprazole showed significantly less EPS liability as assessed by the Simpson-Angus Scale (p < .005) and less serum prolactin level elevation (p < .001) than risperidone. Both groups showed mild weight gain. No patients showed clinically significant QTc interval prolongation in this study. Conclusion: Compared with risperidone 6 mg/day, aripiprazole 15 mg/day has comparable efficacy and favorable safety and tolerability profiles in the short-term treatment of Chinese patients with acute schizophrenia. In this group of Chinese patients, the overall response to aripiprazole did not differ from that of white patients. Clinical Trials Registration: ClinicalTrials.gov identifier NCT00283179. | en_US |
dc.relation.ispartof | Journal of Clinical Psychiatry | en_US |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | aripiprazole; benzatropine; benzodiazepine; placebo; risperidone; adult; aged; akathisia; anxiety disorder; article; Chinese; cholesterol blood level; clinical trial; constipation; controlled clinical trial; controlled study; dizziness; double blind procedure; drug dose regimen; drug dose titration; drug efficacy; drug safety; drug tolerability; drug withdrawal; dyskinesia; extrapyramidal symptom; female; glucose blood level; human; insomnia; liver dysfunction; major clinical study; male; parkinsonism; priority journal; prolactin blood level; psychosis; QT prolongation; randomized controlled trial; rating scale; schizoaffective psychosis; schizophrenia; short course therapy; side effect; treatment response; vomiting; weight gain | - |
dc.title | Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: A randomized trial | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.4088/JCP.v68n0104 | - |
dc.identifier.pmid | 17284127 | - |
dc.identifier.scopus | 2-s2.0-33846860210 | - |
dc.relation.pages | 29-36 | en_US |
dc.relation.journalvolume | 68 | en_US |
dc.relation.journalissue | 1 | en_US |
item.fulltext | no fulltext | - |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Psychiatry | - |
crisitem.author.dept | Psychiatry-NTUH | - |
crisitem.author.dept | Brain and Mind Sciences | - |
crisitem.author.dept | Neurobiology and Cognitive Science Center | - |
crisitem.author.dept | Center for Integrated Dementia Care | - |
crisitem.author.dept | Psychiatry | - |
crisitem.author.dept | Psychiatry-NTUH | - |
crisitem.author.dept | Epidemiology and Preventive Medicine | - |
crisitem.author.dept | Psychology | - |
crisitem.author.dept | Neurobiology and Cognitive Science Center | - |
crisitem.author.orcid | 0000-0001-7894-9484 | - |
crisitem.author.orcid | 0000-0002-2582-2807 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | Others: University-Level Research Centers | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Public Health | - |
crisitem.author.parentorg | College of Science | - |
crisitem.author.parentorg | Others: University-Level Research Centers | - |
顯示於: | 醫療器材與醫學影像研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。